Skip to main content

Table 1 Baseline patient characteristics of patients with esophageal squamous cell carcinoma

From: Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma

Clinicopathological Total
variables N = 64 (%)
Sex
 Male/Female 60 (93.8)/4 (6.2)
Age, median years 63.5
Smoking (pack-yrs)
 Light/Heavy 29 (45.3)/35 (54.7)
Alcohol (drink/week)  
 Light/Heavy 32 (50.0)/32 (50.0)
Location
 Upper/Middle/Lower 14 (21.9)/31 (48.4)/19 (29.7)
Tumor size, median (range, mm) 36.5 (8–105)
Differentiation
 Well/Moderate/Poor 26 (40.6)/26 (40.6)/12 (18.8)
pT category
 T1/T2/T3/T4 27 (42.2)/9 (14.1)/27 (42.2)/1 (1.5)
pN category
 N0/N1/N2/N3 39 (60.9)/14 (21.9)/7 (10.9)/4 (6.3)
pM category
 M0/M1 64 (100)/0 (0)
AJCC stage (8th)
 IA/IB 3 (4.7)/23 (35.9)
 IIA/IIB 9 (14.1)/5 (7.8)
 IIIA/IIIB 4 (6.3)/15 (23.4)
 IVA 5 (7.8)
Treatment
 Surgery alone 47 (73.4)
 Surgery and CT 7 (10.9)
 Surgery and RT 1 (1.6)
 Surgery and CCRT 9 (14.1)
Resection margin status
 Negative (R0)/Positive (R1) 57 (89.1)/7 (10.9)
Recurrence
 No/Yes 24 (37.5)/40 (62.5)
Survival status (at follow-up)
 Alive/Dead 26 (40.6)/38 (59.4)
Family history of malignancy 2 (3.1)
Metachronous/synchronous malignancy 17 (26.6)
  1. CT chemotherapy, RT radiotherapy, CCRT concurrent chemoradiation therapy